Tumor radioimmunolocation: differential antibody retention by antigenic normal tissue and tumor.
On the assumption that a high specificity would be required for in vivo tumor location and drug targeting, much labor has been expended to produce monoclonal antibodies directed to antigens found primarily on tumors. However, for at least one tumor-associated antigen, stage-specific embryonic antigen 1 (SSEA-1), the concentration of the target antigen need not be higher in the tumor than that found in normal tissues for successful use of the corresponding monoclonal antibody in in vivo tumor location; rather, accessibility and antibody metabolism are more important.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D000915:Antibody Affinity; D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology*; D000954:Antigens, Surface / Q000032:analysis / Q000276:immunology; D001921:Brain / Q000276:immunology; D006017:Glycolipids / Q000032:analysis / Q000276:immunology*; D007668:Kidney / Q000276:immunology; D016256:Lewis X Antigen; D008099:Liver / Q000276:immunology; D051379:Mice; D012469:Salivary Glands / Q000276:immunology; D013724:Teratoma / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D006017:Glycolipids; D016256:Lewis X Antigen